- Home
- AG vs SLNO Comparison
AG vs SLNO Comparison
Compare AG & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | SLNO |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 2.3B |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AG | SLNO |
|---|---|---|
| Price | $22.12 | $37.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $21.92 | ★ $105.27 |
| AVG Volume (30 Days) | ★ 18.3M | 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | $13.75 | $150.65 |
| Revenue Next Year | $26.43 | $56.10 |
| P/E Ratio | $143.01 | ★ $85.77 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $5.19 | $29.43 |
| 52 Week High | $32.00 | $89.12 |
Technical Indicators
Market Signals| Indicator | AG | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 54.76 |
| Support Level | $20.21 | $32.63 |
| Resistance Level | $27.90 | $41.48 |
| Average True Range (ATR) | 1.44 | 2.12 |
| MACD | 0.02 | 0.34 |
| Stochastic Oscillator | 65.61 | 87.91 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.